Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 105,723
  • Shares Outstanding, K 8,164
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,490 K
  • 60-Month Beta 1.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.65
Trade ANVS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -1.21
  • Number of Estimates 1
  • High Estimate -1.21
  • Low Estimate -1.21
  • Prior Year -0.75
  • Growth Rate Est. (year over year) -61.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.39 +13.70%
on 11/09/22
14.39 -10.01%
on 11/15/22
+0.39 (+3.11%)
since 10/28/22
3-Month
10.14 +27.71%
on 09/07/22
23.91 -45.84%
on 09/15/22
+1.70 (+15.11%)
since 08/26/22
52-Week
8.39 +54.44%
on 05/12/22
25.90 -50.00%
on 11/29/21
-12.81 (-49.73%)
since 11/26/21

Most Recent Stories

More News
Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 239%: Here's is How to Trade

The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 239.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...

ANVS : 12.95 (-3.21%)
Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update

/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases,...

ANVS : 12.95 (-3.21%)
Annovis Bio to Present at the 2022 ThinkEquity Investor Conference

/PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced...

ANVS : 12.95 (-3.21%)
Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease

/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases,...

ANVS : 12.95 (-3.21%)
Annovis (ANVS) Gains on FDA Authorization for AD Study

Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).

BIIB : 294.00 (+0.72%)
LLY : 365.77 (+0.14%)
PRTA : 56.71 (-7.35%)
ANVS : 12.95 (-3.21%)
Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease

/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases,...

ANVS : 12.95 (-3.21%)
Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference

/PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced...

ANVS : 12.95 (-3.21%)
Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases

/PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced...

ANVS : 12.95 (-3.21%)
Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders

/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases,...

ANVS : 12.95 (-3.21%)
Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer

/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases,...

ANVS : 12.95 (-3.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 14.40
2nd Resistance Point 14.07
1st Resistance Point 13.51
Last Price 12.95
1st Support Level 12.62
2nd Support Level 12.29
3rd Support Level 11.73

See More

52-Week High 25.90
Fibonacci 61.8% 19.21
Fibonacci 50% 17.14
Fibonacci 38.2% 15.08
Last Price 12.95
52-Week Low 8.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar